Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

May 12, 2022 07:30 ET | Source: Xilio Therapeutics, Inc.

Xilio Therapeutics Reports Pipeline and Business Highlights and First Quarter 2022 Financial Results

Clinical programs for XTX202, a tumor-selective IL-2, and XTX101, a tumor-selective anti-CTLA-4, continue to advance with preliminary data anticipated in 2022 On track with plans to submit IND for...
April 07, 2022 06:30 ET | Source: Xilio Therapeutics, Inc.

Xilio Therapeutics to Present at the 21st Annual Needham Virtual Healthcare Conference

WALTHAM, Mass., April 07, 2022 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (Nasdaq: XLO), a biotechnology company developing tumor-selective immuno-oncology therapies for people living with cancer,...
March 01, 2022 06:30 ET | Source: Xilio Therapeutics, Inc.

Xilio Therapeutics Reports Pipeline and Business Progress and Fourth Quarter and Full Year 2021 Financial Results

Initial Phase 1 Data Readouts from Clinical Trials of XTX101 and XTX202 Anticipated in 2022 On Track with Plans to Submit IND for XTX301 in Second Half of 2022 Continue to Anticipate Cash Runway...
February 28, 2022 06:30 ET | Source: Xilio Therapeutics, Inc.

Xilio Therapeutics to Participate in the Cowen 42nd Annual Healthcare Conference

WALTHAM, Mass., Feb. 28, 2022 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (Nasdaq: XLO), a biotechnology company developing tumor-selective immuno-oncology therapies for people living with cancer,...
February 03, 2022 06:30 ET | Source: Xilio Therapeutics, Inc.

Xilio Therapeutics to Participate in the Guggenheim 4th Annual Oncology Day

WALTHAM, Mass., Feb. 03, 2022 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (Nasdaq: XLO), a biotechnology company developing tumor-selective immuno-oncology therapies for people living with cancer,...
January 20, 2022 07:30 ET | Source: Xilio Therapeutics, Inc.

Xilio Therapeutics Announces Initiation of Patient Dosing in Phase 1/2 Clinical Trial of XTX202 for the Treatment of Patients with Solid Tumors

WALTHAM, Mass., Jan. 20, 2022 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (Nasdaq: XLO), a biotechnology company developing tumor-selective immuno-oncology therapies for people living with...
January 06, 2022 07:30 ET | Source: Xilio Therapeutics, Inc.

Xilio Therapeutics Appoints Yuan Xu, Ph.D., to its Board of Directors

WALTHAM, Mass., Jan. 06, 2022 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (Nasdaq: XLO), a biotechnology company developing tumor-selective immuno-oncology therapies for people living with cancer,...
December 02, 2021 07:30 ET | Source: Xilio Therapeutics, Inc.

Xilio Therapeutics Reports Pipeline and Business Progress and Third Quarter 2021 Financial Results

Anticipate First Patient Dosing in Phase 1/2 Clinical Trial for XTX202, a Tumor-Selective IL-2, in First Quarter of 2022 Advancing Phase 1/2 Clinical Trial for XTX101, a Tumor-Selective Anti-CTLA-4...
November 12, 2021 07:00 ET | Source: Xilio Therapeutics, Inc.

Xilio Therapeutics Announces Preclinical Data Demonstrating Anti-Tumor Activity and Tolerability of XTX301, a Tumor-Selective IL-12, at Society for Immunotherapy in Cancer Annual Meeting

WALTHAM, Mass., Nov. 12, 2021 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (Nasdaq:XLO), a biotechnology company developing tumor-selective immuno-oncology therapies for patients with cancer, today...
October 26, 2021 16:05 ET | Source: Xilio Therapeutics, Inc.

Xilio Therapeutics Announces Closing of Initial Public Offering

WALTHAM, Mass., Oct. 26, 2021 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (Xilio) a biotechnology company developing tumor-selective immuno-oncology therapies for patients with cancer, today...